News
SCYX
4.835
-6.21%
-0.320
SCYNEXIS Swings To Q2 Profit; Expects Phase 1 Topline Data For SCY-770 In Q3 2026;Stock Up
NASDAQ · 1d ago
Scynexis reports Q2 EPS 63c, consensus (51c)
TipRanks · 1d ago
*Scynexis 2Q EPS 63c >SCYX
Dow Jones · 1d ago
Weekly Report: what happened at SCYX last week (0803-0807)?
Weekly Report · 2d ago
Weekly Report: what happened at SCYX last week (0727-0731)?
Weekly Report · 08/03 10:09
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 07/31 17:05
GSK closer to relaunching Brexafemme, says Brookline
TipRanks · 07/31 15:50
Weekly Report: what happened at SCYX last week (0720-0724)?
Weekly Report · 07/27 10:13
Weekly Report: what happened at SCYX last week (0713-0717)?
Weekly Report · 07/20 10:10
Weekly Report: what happened at SCYX last week (0706-0710)?
Weekly Report · 07/13 10:11
Weekly Report: what happened at SCYX last week (0629-0703)?
Weekly Report · 07/06 10:15
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX)
TipRanks · 07/02 08:30
Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained
TipRanks · 07/01 19:25
Scynexis initiates SCY-770 study
TipRanks · 06/30 12:11
SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing Regimens
Benzinga · 06/30 12:02
Weekly Report: what happened at SCYX last week (0622-0626)?
Weekly Report · 06/29 10:10
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes
TipRanks · 06/26 20:39
Weekly Report: what happened at SCYX last week (0615-0619)?
Weekly Report · 06/22 10:18
Weekly Report: what happened at SCYX last week (0608-0612)?
Weekly Report · 06/15 10:19
Weekly Report: what happened at SCYX last week (0601-0605)?
Weekly Report · 06/08 10:15
More
Webull provides a variety of real-time SCYX stock news. You can receive the latest news about Scynexis through multiple platforms. This information may help you make smarter investment decisions.
About SCYX
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).